Haemophilia : the official journal of the World Federation of Hemophilia
Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors.
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita
Published: 202510.1111/hae.70162
Abstract
INTRODUCTION: The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. AIM: To monitor long-term safety and effectiveness of emicizumab, including appropriate concomitant…
Preview only. Read the full abstract at the source